BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       

«Yersinia Infections

Below is an extended Yersinia Infections research listing. Click here to return to the Yersinia Infections main in depth entry.

Recent Publications on Yersinia Infections:

[Humoral response to selected antigens of Yersinia enterocolitica and Yersinia pseudotuberculosis in the course of yersiniosis in humans. IV. Specificity of antigens] 30th August, 2008
Zaklad Bakteriologii
Prevalence of Yersinia enterocolitica in market weight hogs in the United States. 12th August, 2008
US Department of Agriculture, Agricultural Research Service, National
Contribution of trimeric autotransporter C-terminal domains of oligomeric coiled-coil adhesin (Oca) family members YadA, UspA1, EibA, and Hia to translocation of the YadA passenger domain and virulence of Yersinia enterocolitica.
The Oca family is a novel class of autotransporter-adhesins with highest...
Direct Link
5th August, 2008
Max von Pettenkofer Institute for Hygiene and Medical Microbiology, Ludwig
Susceptibility of four inbred mouse strains to a low-pathogenic isolate of Yersinia enterocolitica.
EUMORPHIA (European Union Mouse Research for Public Health and Industrial...
Direct Link
22nd July, 2008
Department of Experimental Immunology, Helmholtz Centre for Infection
A Csr-type regulatory system, including small non-coding RNAs, regulates the global virulence regulator RovA of Yersinia pseudotuberculosis through RovM.
The MarR-type regulator RovA controls expression of virulence genes of...
Direct Link
17th July, 2008
Institut fur Mikrobiologie, Technische Universitat Braunschweig, 38106
RNase E regulates the Yersinia type 3 secretion system.
Yersinia spp. use a type 3 secretion system (T3SS) to directly inject six...
Direct Link
17th July, 2008
University of Miami, Miller School of Medicine, Department of Microbiology
Crosstalk of signalling processes of innate immunity with Yersinia Yop effector functions.
The interaction of microbial pathogens with host cells critically...
Direct Link
10th July, 2008
Institute for Medical Microbiology, Virology and Hygiene, University
Biochemical functions of Yersinia type III effectors.
Yersinia uses a type III secretion system (TTSS) to deliver six effector...
Direct Link
28th May, 2008
National Institute of Biological Sciences, Zhongguancun Life Science Park,
Resistance of chemokine receptor 6-deficient mice to Yersinia enterocolitica infection: evidence of defective M-cell formation in vivo.
M cells, specialized cells within Peyer's patches (PPs), are reduced in...
Direct Link
10th May, 2008
Department of Medicine B, University of Muenster, Albert-Schweitzer
[Medical rehabilitation and follow-up of patients with yersiniosis] 2nd April, 2008
Axillary abscess in a patient with Yersinia enterocolitica infection as a result of exposure to pork.
Yersinia spp. use a type 3 secretion system (T3SS) to directly inject six...
Direct Link
28th March, 2008
Division of Infectious Diseases, Caritas Saint Elizabeth's Medical Center,
Hypoxia-independent activation of HIF-1 by enterobacteriaceae and their siderophores.
BACKGROUND & AIMS: Hypoxia inducible factor-1 (HIF-1) is the key...
Direct Link
21st March, 2008
Institut fur Medizinische Mikrobiologie und Hygiene, Universitatsklinikum
Short- and long-term effects of bacterial gastrointestinal infections. 12th March, 2008
Department of Medical Epidemiology and Biostatistics, Karolinska
Serum immunoglobulin IgG subclass distribution of antibody responses to Yop proteins and lipopolysaccharide of Yersinia enterocolitica in patients with yersiniosis. 5th March, 2008
Department of Bacteriology, National Institute of Hygiene, Warsaw, Poland.
Reactive arthritis following culture-confirmed infections with bacterial enteric pathogens in Minnesota and Oregon: a population-based study.
OBJECTIVE: To describe the epidemiology and clinical spectrum of ReA...
Direct Link
15th February, 2008
Oregon Health & Science University, United States.
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

BioPortfolio logo

Valid XHTML 1.0 Transitional